Search Tag: Hologic
Hologic to Announce Financial Results for the Second Quarter of Fiscal 2015 on Wednesday, April 29
2015 06 Apr
BEDFORD, Mass. , / PRNewswire / -- Hologic, Inc. (NASDAQ: HOLX) announced that the Company plans to release its operating results for the second quarter of fiscal 2015 on Wednesday, April 29, 2015 , after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time . Interested participants... Read more
Hologic Delivers Notice that Holders of 2.00%
2015 01 Apr
BEDFORD, Mass. ,/ PRNewswire / -- Hologic, Inc. (NASDAQ: HOLX) announced that it has notified holders of the 2.00% Convertible Exchange Senior Notes due 2037 (CUSIP No. 436440 AB7) issued November 23, 2010 , and Wilmington Trust Company, the trustee, paying agent and conversion agent for the notes, that holders are eligible to convert the notes. ... Read more
#ECR2015: Hologic Satellite Symposium: Screening with Breast Tomosynthesis: An Emerging Reality
2015 26 Feb
The amount of clinical proof for the efficacy of Tomosynthesis in screening is significantly larger than the proof available in the early days of the transition from analog mammography to FFDM. Results from studies in Europe using Tomosynthesis in population based screening and results from screening with Tomosynthesis in the USA are concordant... Read more
Three New Peer-Reviewed Publications Further Validate the Benefits of Hologic Tomosynthesis
2014 12 Feb
Research supports the use of Hologic's lower dose 3D mammography technology and the continued use of two-views over one in breast cancer screening Hologic, Inc., a leading developer, manufacturer and supplier of premium diagnostic products, medical imaging systems and surgical products, with an emphasis on serving the healthcare needs of women,... Read more
Arab Health 2014: Hologic to Showcase Award-Winning 3D Mammography Platform
2014 28 Jan
With an emphasis on improving lives, Hologic is focused on bringing the latest in diagnostic innovations to the fast growing Gulf region Hologic, Inc., a leading developer, manufacturer and supplier of premium diagnostic products, medical imaging systems and surgical products, with an emphasis on serving the healthcare needs of women, will feature... Read more
RSNA 2013: Hologic to Showcase its 3D Imaging Portfolio
2013 22 Nov
3D Mammography, Hologic's game-changing breast cancer screening technology, is a major focus at the largest radiology gathering in the world Hologic, Inc., a leading developer, manufacturer and supplier of premium diagnostic products, medical imaging systems and surgical products, with an emphasis on serving the healthcare needs of women,... Read more
In Breast Cancer Detection, the Evidence Points to Tomosynthesis
2013 17 Sep
Growing number of peer-reviewed clinical publications document significant advantages of H ologic® tomosynthesis; Now, Hologic has further advanced tomosynthesis with faster and lower-dose options including the C-View™ software option for 2D imaging and the Affirm™ tomosynthesis biopsy procedure. Tomosynthesis is going from strength... Read more
Hologic's Breast Tomosynthesis Reduces Recall Rates and Improves Cancer Detection - U.S. Study
2013 24 May
Hologic has announced that the first large-scale observational study in a U.S. clinical practice comparing breast cancer screening with Hologic's 3D mammography technology (breast tomosynthesis) with conventional 2D mammography alone showed a significant reduction in recall rates and a sizeable increase in cancer detection, particularly invasive cancer,... Read more
Hologic Gets FDA Approval for New Low-Dose Breast Tomosynthesis Solution
2013 24 May
Hologic has announced US Food and Drug Administration approval of its new C-View 2D imaging software. C-View 2D images may now be used in place of the conventional 2D exposure previously required as part of a Hologic 3D mammography (breast tomosynthesis) screening exam. C-View images are generated from the 3D tomosynthesis data acquired during... Read more
Hologic Q2 2013 Results
2013 17 May
Hologic has announced its results for the second fiscal quarter ended March 30, 2013. Highlights Include: Financial: Revenues of $612.7 million, net of a $(6.4) million adjustment related to contingent revenue earned and received under Gen‐Probe Incorporated's (Gen‐Probe) collaboration agreement with Novartis. Non‐GAAP adjusted revenues... Read more